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Current thinking on the development of molecular 
microbial characterisation techniques in public health 
focuses mainly on operational issues that need to be 
resolved before incorporation into daily practice can 
take place. Notwithstanding the importance of these 
operational challenges, it is also essential to formulate 
conditions under which such microbial characterisa-
tion methods can be used from an ethical perspective. 
The potential ability of molecular techniques to show 
relational patterns between individuals with more cer-
tainty brings a new sense of urgency to already dif-
ficult ethical issues associated with privacy, consent 
and a moral obligation to avoid spreading a disease. 
It is therefore important that professionals reflect on 
the ethical implications of using these techniques in 
outbreak management, in order to be able to formu-
late the conditions under which they may be applied in 
public health practice.
Introduction
Recent advances in molecular microbial characterisa-
tion open up new scientific opportunities for a better 
understanding of not only the pathogenicity, evolution 
and spread of human pathogens, but also the epidemi-
ology of the diseases they cause. Such progress has 
promising prospects for infectious disease control, 
particularly for real-time source and contact tracing 
in outbreak management [1]. Current thinking on the 
development of molecular microbiology characterisa-
tion techniques in public health focuses predominantly 
on the operational issues that need to be resolved [1]. 
The recommendations of the November 2011 expert 
consultation Breakthroughs in molecular epidemiology 
of human pathogens - how to translate breakthroughs 
into public health practice, organised by the European 
Centre for Disease Prevention and Control (ECDC), 
clearly outline the scientific hurdles that need to be 
overcome in order for public health to benefit from 
the recent scientific and technological advances in 
the rapidly evolving next generation sequencing tech-
nologies [1]. Despite the importance of these opera-
tional challenges, it is also essential to address the 
ethical difficulties associated with the use of microbial 
characterisation techniques in public health. The need 
for ethical guidance concerning the use of molecular 
typing methods is not new. Ethical challenges stem-
ming from the introduction of molecular genomics have 
often been addressed in the context of population-
level genomics and biobanking; such issues include 
those related to persons’ autonomy and the patient–
healthcare professional relationship. The use of these 
techniques in infectious disease control now raises 
similar ethical issues, in which individual interests and 
individual needs must be weighed against those of the 
public at large [2]. Due to recent scientific and techno-
logical advances in molecular microbial characterisa-
tion, the need for ethical guidance has now gained a 
new sense of urgency [3]. 
Although microbial characterisation techniques have 
primarily (and successfully) been used to benefit the 
general public’s health, the results can also be used 
for other purposes, notably in support of legal or moral 
claims about responsibility and liability. For example, 
in 2007, in the Netherlands, genetic sequence analysis 
of HIV strains was used in a criminal case, in which the 
plaintiffs, who were recently infected with HIV, accused 
the defendants of deliberately administering them a 
subcutaneous injection of HIV-positive blood. The com-
parison of the genetic sequence analysis of the HIV 
strains of both parties was used as legal evidence [4].
Another example is a listeriosis outbreak linked to a 
food facility near Toronto, Canada, in 2008 [2]. Public 
health officials initially responded to the outbreak 
using traditional contact tracing and outbreak inves-
tigation. The food facility issued a voluntary recall of 
cold meat products before a confirmed linkage was 
available. Typing was used retrospectively to reduce 
uncertainty about the link between the 100 confirmed 
cases (23 deaths) and exposure to contaminated 
food from the facility. The resulting class-action law-
suits filed in four Canadian provinces were settled in 
December 2008 for US$ 27 million. 
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In these examples, the approach was successful from 
a medical perspective; however, from an ethical per-
spective, information that was initially collected for 
the purpose of public health was then also used in a 
legal context. Thus the results of genetic sequencing 
of infectious agents for purposes that go beyond pro-
tection of public health can yield important societal 
benefits, but can also facilitate legal claims (and hence 
economic risk) for individual persons or companies. 
And even in cases where individual persons or com-
panies could do little to prevent an outbreak or avoid 
being a causal factor in transmitting disease, public 
perception of responsibility for infection may easily 
lead to stigmatisation and thus negatively affect the 
lives of the persons involved. 
In this context, we highlight the most dominant ethi-
cal issues in regard to the use of molecular techniques. 
This is to facilitate further ethical reflection by pub-
lic health professionals regarding the use of molecu-
lar techniques. We use the term to refer to a range of 
molecular microbial characterisation techniques that 
enable the linking of pathogens and that are now 
becoming increasingly available for real-time source 
and contact tracing.
Relational patterns between pathogens 
and people: a sense of urgency to 
the existing ethical debate 
The ethical challenges associated with molecular tech-
niques are mostly linked to their ability to give more 
precise information on the relational patterns between 
different microbes found in an outbreak [5-7]. Although 
the results of such techniques must be understood in 
the context of traditional epidemiological information 
– and even then, the most probable transmission route 
is rarely the only one possible – molecular techniques 
can allow more certainty on the relational patterns 
between microbes found in an outbreak. This inference 
about the directionality of transmission, may however, 
also specify the relational patterns between the people 
hosting them. This may be perceived by the public as 
an answer to the ‘who infected whom?’ question in an 
outbreak. While the ethical issues related to this ques-
tion are not new, molecular techniques may heighten 
the level of certainty regarding such patterns and in 
this way introduce a sense of urgency to the ethical 
debate [8,9].
Moral obligation to avoid 
spreading a disease 
That advanced sequencing technologies show poten-
tial relational patterns between people may fuel pub-
lic discussions about who is responsible for infection 
or outbreaks. This is a complex issue with no simple 
conclusions; however, it is tempting to jump from infor-
mation about ‘who infected whom’ to judgments about 
responsibility for infection. Attribution of responsibil-
ity to individuals for outbreaks of infectious diseases, 
however, is ethically problematic, even with the most 
sophisticated microbial molecular typing techniques. 
This is because although molecular microbial typing 
methods can help to elucidate potential transmission 
pathways, additional conditions are required before 
moral responsibility for the spread of infection can be 
attributed to individuals. More advanced molecular 
technology (in combination with epidemiological infor-
mation) may be able to visualise certain transmission 
patterns in an outbreak, but this does not necessarily 
lead to factual conclusions on the cause of disease. 
Transmission of a microbe, for instance, may lead to col-
onisation, but colonisation may not necessarily lead to 
infection or subsequent disease. But even if we assume 
that transmission leads to disease, this does not make 
the source or actor morally responsible. The conditions 
for attributing moral responsibility for spreading a dis-
ease include numerous factors that need to be taken 
into account, for instance, knowledge of the risk, of the 
transmission pathways and ways to avoid infection, as 
well as competence to take adequate precautions [10]. 
Moreover, whether one can rightfully attribute moral 
responsibility will depend on whether it is reasonable 
to expect people to take precautions against infecting 
others and whether the infected persons could have 
easily protected themselves. Hence, judgments about 
moral responsibility are complex: even though molecu-
lar typing technologies may show relatively clear trans-
mission pathways, this should not be considered as a 
sufficient basis for judgments about responsibility 
for infection. This is not to say that the laws of some 
countries may address this moral obligation to avoid 
spreading a disease and have specified what action is 
legally prohibited, required or permissible, attaching 
legal consequences for those who fail to act in line with 
such dictates.
Ownership of pathogens
In addition to this concept of a moral responsibility for 
infection, molecular techniques also place the concept 
of privacy in a new perspective. The question of pri-
vacy is associated in a way with the question of own-
ership. In bioethics, there already is a debate on who 
owns a biological specimen isolated from an individual 
at a certain moment in time [11], regarding whether a 
biological specimen (such as tissue, blood or stool) 
and the pathogen found in this specimen, in some way 
‘belong’ to the individual they came from. In outbreak 
management, this question is further complicated by 
the fact that a number of pathogens are transmissable 
from person to person, which means that they may be 
seen as ‘owned’ by various persons over time. 
Informed consent
Irrespective of the outcome of this ownership debate, 
privacy from a perspective of ethical and legal issues 
surrounding informed consent also need to be 
addressed when molecular techniques are used in 
outbreak management. There are various ethical and 
legal theories or accounts given of what informed con-
sent exactly means and how it should be conducted in 
practice. From an ethical perspective, informed con-
sent is concerned with the consent being ‘informed’, 
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‘voluntary’, and ‘decisionally-capacitated’, meaning 
that all information needs to be disclosed to a com-
petent (‘capacitated’) patient, who understands all 
that has been disclosed, and that this patient volun-
tarily consents to treatment (or to a research subject 
when it comes to participation in research) [12]. This 
raises important questions about how these informed 
consent requirements could be conceptualised when 
using molecular techniques in outbreak management. 
One such question pertains to formulating information 
disclosure requirements: what (type and how much) 
information ought to be disclosed and comprehended 
in order for someone to be able to legitimately consent 
to any type of intervention or procedure proposed by a 
public health official? Intertwined with this is the ques-
tion of who consent must be obtained from. Due to the 
fact that many individuals may be involved in an out-
break, and because sequence information about the 
pathogen in a particular infected individual may give 
rise to new information about, for example, relational 
patterns to other infected persons, the question of 
who exactly, of all the persons involved in an outbreak, 
should be consenting to the use of such technologies 
remains a pertinent one. Such information could be rel-
evant to a number of parties involved in an outbreak 
for different reasons, and the interests of those par-
ties in that information could, moreover, conflict with 
each other. Furthermore, informing all the parties may 
be seen as an unrealistic task, depending on the type 
and amount of information that needs to be disclosed 
and who must be informed. This is also relevant to 
the current management of outbreaks, but molecular 
techniques give more specificity about the direction-
ality of transmission and can be used on a pathogen 
obtained from one person and interpreted along with 
information obtained from another person. This makes 
answering the question to whom disclosures should 
be made, who should agree to participate and whether 
full comprehension of the information in itself can be 
reached even more complex. 
Return of results
Another issue that needs to be addressed when using 
molecular techniques in outbreak management is the 
concept of a ‘return of results’ duty. This concept per-
tains to the problem of how and to what extent, or 
whether (research) information needs to be returned 
to certain parties, for instance, the individual and/or 
the public. This is an issue well addressed in biobank-
ing, where the debate focuses on treatment options or 
financial gain [11]. When it comes to outbreak manage-
ment, however, the issue is more complex: here it is 
not only about the (financial or medical) interests of 
specific individuals directly associated with the inter-
vention but also about the many parties involved in an 
outbreak. The interests and needs of specific individu-
als need to balanced with those of the general popula-
tion. Furthermore, disclosure of information may be of 
immediate public health interest and, at the same time, 
be harmful to the people directly involved. 
Legal perspective
A legal norm or duty and its justification are not the 
same as a moral norm or duty and its justification. 
Although the presence and adoption of legal duties are 
frequently justified (usually at least in part) by ethi-
cal arguments, what ultimately validates a legal norm 
is its recognition by a political and/or legal institution 
or authority. That is, a legal norm is operationalised 
through institutional rules and governance structures 
(ranging from laws and regulations to policies and 
guidelines). The law attempts to find a coherent posi-
tion in balancing population interests versus individual 
freedoms [13]. The introduction of novel technologies 
into health systems often brings forth new ethical argu-
ments and this may change the perspective on these 
population interests or individual freedoms. However 
the present legal norm cannot easily be changed and 
cannot even always be directly met by new jurisdiction 
[13]. 
When it comes to the legal framework for controlling 
infectious diseases and the protection of public health; 
using molecular techniques may not even be a problem 
in many European countries [14]. Public health law in 
many countries already makes surveillance legally pos-
sible without explicit patient consent [14]; however, to 
what extent this includes a legal possibility for micro-
biological research and molecular typing in outbreak 
management is not well defined. 
Conclusion
In light of the ability of molecular techniques to show 
potential relational patterns between people and that 
this may fuel public discussions about who is respon-
sible for an infection or outbreaks, it is essential to not 
only address operational challenges related to use of 
such techniques in outbreak management, but also to 
shape the conditions under which they can be used in 
practice. Reflection on these conditions may not result 
in closure of the ethical debate on topics such as pri-
vacy, consent and moral obligation to avoid infecting 
others, but it can offer guidance to public health pro-
fessionals who use these techniques in source and 
contact tracing. 
Call for ethical reflection
In this context, the Dutch Municipal Health Service GGD 
Midden-Nederland focuses on the ethical questions 
concerning the use of molecular typing techniques in 
the control of infectious diseases. Our current pro-
ject, supported by the Dutch National Institute for 
Public Health and the Environment (RIVM) through 
the regional support fund for reinforcement of infec-
tious disease control, aims at combining public health 
ethics with practice. We warmly invite public health 
professionals, especially microbiologists, to put their 
reflections on the conditions under which molecular 
techniques should be used in source and contact trac-
ing in writing (send them by email to ethiektraining@
ggdmn.nl before 15 March 2013).
4 www.eurosurveillance.org
Acknowledgments 
This work is funded by the Dutch Ministry of Health Welfare 
and Sport, RIVM, through the regional support fund for rein-
forcement of infectious disease control.
References
1. Palm D, Johansson K, Ozin A, Friedrich AW, Grundmann 
H, Larsson JT, et al. Molecular epidemiology of human 
pathogens: how to translate breakthroughs into public 
health practice. Stockholm, November 2011. Euro Surveill. 
2012;17(2):pii=20054. Available from: http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=20054 
2. Fanoy E, De Neeling A. Molecular typing: use with care. Public 
Health Ethics. 2012;5(3):313-4. 
3. Rump B, Woonink F. Ethical questions concerning the use 
of molecular typing techniques in the control of infectious 
diseases. Public Health Ethics. 2012;5(3):311-3. 
4. van der Kuyl AC, Jurriaans S, Back NK, Sprenger HG, van der 
Werf TS, Zorgdrager F, et al. Unusual cluster of HIV type 1 
dual infections in Groningen, the Netherlands. AIDS Res Hum 
Retroviruses. 2011;27(4):429-33. 
5. van Belkum A. Molecular typing of micro-organisms: at the 
centre of diagnostics, genomics and pathogenesis of infectious 
diseases? J Med Microbiol. 2002;51(1):7-10. 
6. Kretzschmar M, Gomes MG, Coutinho RA, Koopman 
JS. Unlocking pathogen genotyping information for 
public health by mathematical modeling. Trends 
Microbiol.2010;18(9):406-12. 
7. Patel SJ, Graham PL 3rd. Use of molecular typing in infection 
control. Pediatr Infect Dis J. 2007;26(6):527-9. 
8. Harris J, Holm S. Is there a moral obligation not to infect 
others? BMJ. 1995;311(7014):1215–7. 
9. Verweij M. Obligatory precautions against infection. Bioethics. 
2005;19(4):323-35. 
10. Millar M. Moral permissibility and responsibility for infection. 
Public Health Ethics. 2012;5(3):314-7. 
11. Hawkins AK, O’Doherty KC. “Who owns your poop?”: insights 
regarding the intersection of human microbiome research and 
the ELSI aspects of biobanking and related studies. BMC Med 
Genomics. 2011;4:72. 
12. Informed consent. In: Stanford Encyclopaedia of Philosophy, 
Stanford, CA: Stanford University. [Accessed 12 Dec 
2012]. Available from: http://plato.stanford.edu/entries/
informed-consent/ 
13. Bubela T, Yanow S. Molecular typing technology: a legal 
perspective. Public Health Ethics. 2012;5(3):317-20. 
14. Lee LM, Heilig CM, White A. Ethical Justification for Conducting 
Public Health Surveillance Without Patient Consent. Am J 
Public Health. 2012;102(1):38-44.
